title: Effects of lipopolysaccharide endotoxin on the insulin-like growth factor I system in rats with cirrhosis.
abstract: BACKGROUND
  Patients with liver cirrhosis have disturbances in the insulin-like growth factor I (IGF-I) system that favour insulin resistance and catabolism. High morbidity and mortality of such patients from infections may be related to further aggravation of this problem but human data are controversial. Here, the effect of lipopolysaccharide (LPS) endotoxin on the IGF system was studied in rats with cirrhosis.
  
  
  METHODS
  One month after induction of cirrhosis by bile duct ligation, LPS was administered (0.5 mg/kg) and the IGF system assessed 24 h later. Sham-operated animals acted as controls. Circulating and liver mRNA of IGF-I and its binding proteins (IGFBPs) were measured.
  
  
  RESULTS
  LPS reduced IGF-I and IGFBP-3 by 20% in the cirrhosis group. LPS induced insulin resistance (HOMA) in both groups.
  
  
  CONCLUSIONS
  Our results show that LPS administered to cirrhotic rats induced changes in the IGF system that facilitate catabolism. This may be of importance for the accelerated tissue loss during infection and the acute phase response in liver cirrhosis.
authors.affiliation: Department of Medicine V (Hepatology and Gastroenterology), Clinical Institute, Aarhus University Hospital, DK-8000 Aarhus C, Denmark. kltho@as.aaa.dk
authors.forename: Karen Louise
authors.initials: KL
authors.lastname: Thomsen
authors.forename: Susanne Schouw
authors.initials: SS
authors.lastname: Nielsen
authors.forename: Henning
authors.initials: H
authors.lastname: Grønbiek
authors.forename: Allan
authors.initials: A
authors.lastname: Flyvbjerg
authors.forename: Hendrik
authors.initials: H
authors.lastname: Vilstrup
mesh_terms: D000818:Animals; D001652:Bile Ducts / Q000502:physiology; D001786:Blood Glucose / Q000378:metabolism; D004731:Endotoxins / Q000494:pharmacology*; D005260:Female; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000235:genetics / Q000378:metabolism; D018969:Insulin-Like Growth Factor Binding Proteins / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000503:physiopathology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001786:Blood Glucose; D004731:Endotoxins; D007328:Insulin; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins; D008070:Lipopolysaccharides; D012333:RNA, Messenger; D007334:Insulin-Like Growth Factor I